Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +45.04%
#3 龙虾 (Lobster) 龙虾 (Lobster) +23.45%
#4 DigiByte DigiByte +22.53%
#5 Pons Pons +21.97%
#6 OriginTrail OriginTrail +19.97%
#7 Non-Playable Coin Non-Playable Coin +18.21%
#8 ApeX ApeX +17.96%
#9 Zora Zora +17.33%
#10 Morpho Morpho +16.16%
Coin of the day
Smilek to the Bank Smilek to the Bank
設定
言語
日本
通貨
USD
テーマ
Cyteir Therapeutics, Inc. Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYT
株式のランク #21570
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.
株価
$3.01
最終同期: 2024-04-12
時価総額
$104.64M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Cyteir Therapeutics, Inc. (CYT)

カテゴリー

Healthcare
Cyteir Therapeutics, Inc.（CYT）のEPS
2026 時点のEPS TTM: 0
Cyteir Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Cyteir Therapeutics, Inc.のEPS履歴（2026から2026まで）
各年末時点のEPS
年 EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH